TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05377593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eminoplasty with patient specific Zirconium dioxide onlay implant
Description: Eminoplasties will be done for patient with chronic condylar dislocation using patient specific zirconium dioxide implants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eminoplasty with patient specific Zirconium dioxide onlay implant
Description: Eminoplasties will be done for patient with chronic condylar dislocation using patient specific zirconium dioxide implants
Study: NCT06159257

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test
Description: Whenever possible, samples will be collected by the nurse in the patient's home, according to the study visit schedule. However, if this is not possible, patients will be asked to come in for sample collection at another mutually convenient time at the CERBA ALLIANCE LABORATORY closest to the patient's address.~Venous blood will be drawn on each visit.
Study: NCT04746833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUMMIT
Description: multicomponent web-based application focused on pain self-management skills

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: My Pain Diary app
Study: NCT05589480

Intervention type: OTHER
Intervention: preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
Description: preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
Study: NCT06388252

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrochemotherapy with Intratumoral Cysplatin
Description: ECT will be performed directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
Study: NCT04972734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: premature newborns developing a NEC
Description: weekly Blood sample and daily Stools sample during 12 weeks + Blood and stool sample during NEC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: premature newborns without NEC
Description: weekly Blood sample and daily Stools sample during 12 weeks
Study: NCT05536193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Metformin Emulgel and salicylic acid
Description: Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Insulin- Like growth factor (ILGF-1)
Description: 3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
Study: NCT05055570

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06323486

Intervention type: DEVICE
Group type: OTHER
Intervention: active accelerated bilateral sequential theta burst stimulation and sham treatment
Description: We shall use the Magpro device (Magventure) employing the specialized Active/Sham B70 coil.~absTBS shall be administered consisting of 6 sessions daily (with a 50-minute interval between treatment sessions) on Mondays to Fridays or for a maximum of 5 working days of daily treatment. The target stimulation intensity will be set at 90 to 120% of the subject's resting motor threshold (RMT). Each session shall be composed of administration of continuous theta burst stimulation (triplet burst pulses at 50 Hz, repeated at 5 Hz, for a total of 600 pulses per session over 40 seconds administered on the right dorsolateral prefrontal cortex) and then intermittent theta burst stimulation (triplet burst pulses at 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, for a total of 600 pulses per session over about 3 min, administered on the left dorsolateral prefrontal cortex).~The sham treatment will be conducted for the same number of sessions and duration as the absTBS treatment sessions.

Intervention type: DEVICE
Group type: OTHER
Intervention: active accelerated bilateral sequential theta burst stimulation and sham treatment
Description: We shall use the Magpro device (Magventure) employing the specialized Active/Sham B70 coil.~absTBS shall be administered consisting of 6 sessions daily (with a 50-minute interval between treatment sessions) on Mondays to Fridays or for a maximum of 5 working days of daily treatment. The target stimulation intensity will be set at 90 to 120% of the subject's resting motor threshold (RMT). Each session shall be composed of administration of continuous theta burst stimulation (triplet burst pulses at 50 Hz, repeated at 5 Hz, for a total of 600 pulses per session over 40 seconds administered on the right dorsolateral prefrontal cortex) and then intermittent theta burst stimulation (triplet burst pulses at 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, for a total of 600 pulses per session over about 3 min, administered on the left dorsolateral prefrontal cortex).~The sham treatment will be conducted for the same number of sessions and duration as the absTBS treatment sessions.
Study: NCT06044532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated. At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.
Study: NCT06388252

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrochemotherapy with Intravenous Bleomycin
Description: ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
Study: NCT06187324

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biomarkers
Description: by th use of perio paper GCF was collected and Biomarkers level was estimated
Study: NCT05669300

Intervention type: PROCEDURE
Intervention: Yilmaz Suturation
Description: uterine closure with Yilmaz Technique and single layer continue locked suturation
Study: NCT05314881

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TNFS4, NCF gene
Description: study the gene polymorphisms from the blood sample of the included SLE patients
Study: NCT06224517

Intervention type: OTHER
Intervention: Rehabilitation
Description: The intervention includes daily physical and occupational therapy sessions tailored to each patient's functional status. In this study, stroke patients will undergo a four-week rehabilitation therapy program comprising 60-minute daily sessions of physical and occupational therapy. The physical therapy includes balance training, mobility and strengthening exercises, while occupational therapy covers sensorimotor and fine motor training, and ADL activities.
Study: NCT05390749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib will be given as 150mg orally d1-d21 for 6 cycles,every 21 days for 1 cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be given as 4mg d1-d14 for 4 cycles,every 21 days for 1 cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
Study: NCT04632394

Intervention type: DIAGNOSTIC_TEST
Intervention: Generation of computational model from cardiac MRI.
Description: Routine cardiac MRI scan results will be sent to Johns Hopkins University where a computer-generated model of the heart will be made, which will demonstrate predicted areas critical to VT generation and maintenance. This data will be sent back to St George's, and integrated with the standard VT ablation mapping software to allow comparison of its accuracy with standard mapping techniques.

Intervention type: PROCEDURE
Intervention: VT ablation
Description: Routine VT ablation as described elsewhere in the literature. However, a brief period of extra time (\~30 minutes) will be spent analysing the areas of the heart which the MRI scan predicted as being important for generation of VT. We will study the effect of ablation of these areas (if indicated) on distant parts of the heart.
Study: NCT05302310

Intervention type: OTHER
Intervention: integrated care
Description: i) Screening of older people for risk of frailty using a frailty screening tool, to identify the appropriate care they will require:~* Older adults with low risk of frailty will receive health promotion and preventive care from the Information and Advice Center nurse and/or social worker.~* Older adults at risk will receive the following:~ii) a Comprehensive Geriatric Assessment (CGA) delivered by the Information and Advice Center nurse and social worker over the course of multiple appointments, to identify the health and social care needs and goals of the older person; iii) Development of an individualized care plan by a multidisciplinary team, which will include evidence-based interventions and be coordinated by the Information and Advice Center nurse and/or the social worker; and iv) follow-up depending on the situation of each older person, and adaptation of the individualized care plan, as needed.

Intervention type: OTHER
Intervention: integrated care
Description: i) Screening of older people for risk of frailty using a frailty screening tool, to identify the appropriate care they will require:~* Older adults with low risk of frailty will receive health promotion and preventive care from the Information and Advice Center nurse and/or social worker.~* Older adults at risk will receive the following:~ii) a Comprehensive Geriatric Assessment (CGA) delivered by the Information and Advice Center nurse and social worker over the course of multiple appointments, to identify the health and social care needs and goals of the older person; iii) Development of an individualized care plan by a multidisciplinary team, which will include evidence-based interventions and be coordinated by the Information and Advice Center nurse and/or the social worker; and iv) follow-up depending on the situation of each older person, and adaptation of the individualized care plan, as needed.
Study: NCT05285579

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: Systematic extra blood sampling at inclusion, 6 weeks after inclusion and in case of progression of the cancer

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: Systematic extra blood sampling at inclusion, 6 weeks after inclusion and in case of progression of the cancer

Intervention type: OTHER
Intervention: Tumour samples
Description: reuse of tumour tissue collect in usual patient care

Intervention type: OTHER
Intervention: Tumour samples
Description: reuse of tumour tissue collect in usual patient care
Study: NCT05937529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream containing madecassoside and 5 % panthenol
Description: Immediately after daylight PDT, Cicaplast is administrated as post treatment. The patients are instructed to apply the cream twice daily for 14 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daylight PDT
Description: Daylight PDT performed with 2 hours of artifical indoor light.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daylight PDT
Description: Daylight PDT performed with 2 hours of artifical indoor light.
Study: NCT05866692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-2699a
Description: TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results
Study: NCT05214937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: During the first two weeks (baseline), participants will be asked to maintain their regular movement routine to set a baseline daily average step count. Phases I-III will involve self-regulatory strategies (e.g., action planning), address reducing/interrupting sedentary time, and step counts. Participants will be encouraged to increase their steps by 1000 steps/day from the baseline phase during each subsequent phase (i.e., 3000 steps above baseline by Phase III). Phases IV-V will be a maintenance phase through which participants will be encouraged to maintain 3000 steps per day above baseline. The sessions will be grounded within the Multi-Process Action Control Framework and address perceived capability/opportunity and instrumental/affective attitudes. The 1-on-1 sessions will focus on regulation (action \& coping planning, social support, goal setting) and reflexive processing (self-regulation, habit). The final one on one session will be a booster session to revisit previous topics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FitBit Only
Description: Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living. They will receive a FitBit orientation session with a movement specialist prior to the 12-week control period.
Study: NCT05926063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison short vs extended EBAT treatment group
Description: This study compares two management strategies of patients undergoing treatment with chemotherapy or a stem cell transplantation. One strategy is to treat these patients at the time of febrile neutropenia with a fixed 72 hours course of EBAT. The other, more commonly followed strategy is a longer minimum EBAT duration of 5 days as well as other variables like neutrophil recovery and defervescence. In both arms, definitive treatment is given when an infectious cause of the fever is found according to local guidelines (e.g. pneumonia or mucosits with bacteremia).
Study: NCT04331990

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physcial Therapy
Description: Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle strengthening and stretching, and neuromuscular control exercises. Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Mechanical Traction
Description: In addition to the standard treatment, patients in this group will receive intermittent knee joint decompression for 20 minutes. Patients will be lying supine with the knee semiflexed to 30° and supported by a wedge under the knee. A customized leg cuff will be placed around the lower leg and two ropes will be extending horizontally from the cuff to the vertical traction weight using a pulley system to transfer the traction force to the tibiofemoral articulation. The magnitude of the traction force will be between 10-15% of the patient's body weight. The traction force will be applied for 10 application cycles; each cycle comprised of 2 minutes traction followed by 30 seconds relief. This will sum up to 20 minutes of actual joint traction duration. The traction force application and relief time will be controlled manually by the treating therapist. Knee joint traction procedures will be applied at the end of the physical therapy session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Mechanical Traction
Description: Patients assigned to this group will receive the same treatment protocol as those in the Intermittent Mechanical Traction group. However, the knee traction force will be applied continuously for 20 minutes without intermittent force relief periods.
Study: NCT05390749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: methotrexate 3.5g/m2 civ d1/cycle5-6
Study: NCT04773327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim Injection
Description: 24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle
Study: NCT06147167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: individualized intermittent theta burst sitmulation (iTBS)
Description: Participants undergo daily sessions of individualized intermittent theta-burst stimulation (iTBS) administered with the MagStim stimulator (Rapid2, MagStim, Whiteland, United States). The intervention spans five days a week and extends over a three-week period. In this group, participants receive a personalized iTBS protocol comprising three pulses of stimulation delivered at 50 Hz, repeated every 200 ms. The stimulation frequency is tailored based on the electroencephalogram (EEG) results and is administered every 10 seconds, with a total duration of 190 seconds. The treatment is administered once a day for five days a week and continues for three weeks, with an immediate cessation in case of any discomfort. This study design ensures a meticulous and tailored approach to iTBS administration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard iTBS
Description: The MagStim stimulator (Rapid2, MagStim, Whiteland, United States) was employed in the current study. The intermittent theta-burst stimulation (iTBS) protocol utilized three pulses of stimulation delivered at a frequency of 50 Hz, with a repetition rate of every 200 ms. These pulses were organized into 2-second trains, repeated every 10 seconds, resulting in a cumulative duration of 190 seconds (equivalent to a total of 600 pulses). Notably, the administration of the treatment ceased promptly in the event of any participant discomfort.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The device and protocol are identical to the standard iTBS, with the only difference being the orientation of the coil, which is perpendicular to the scalp.
Study: NCT05103423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 Injection
Description: Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
Study: NCT05926063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison short vs extended EBAT treatment group
Description: This study compares two management strategies of patients undergoing treatment with chemotherapy or a stem cell transplantation. One strategy is to treat these patients at the time of febrile neutropenia with a fixed 72 hours course of EBAT. The other, more commonly followed strategy is a longer minimum EBAT duration of 5 days as well as other variables like neutrophil recovery and defervescence. In both arms, definitive treatment is given when an infectious cause of the fever is found according to local guidelines (e.g. pneumonia or mucosits with bacteremia).
Study: NCT05993793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fototherapy
Description: The Antares brand Laser device was used for 3 sessions with an interval of 24 hours. The Visual Analogue Scale (VAS) was used before starting treatment, after the first and second sessions, and 1 week after the third session. In addition, at the end of the treatment, the closure, or not, of the lesion was verified, and the questionnaires performed prior to phototherapy were reapplied. The VAS assesses the patient's level of pain, which can be divided into mild pain (1-2), moderate pain (3-7), and severe pain (8-10). The Bristol Scale is based on the identification of the patient's consistency of stools, while types 1-2 correspond to constipation, 3-4 indicate normal intestinal rhythm, 5 indicate lack of fiber, and 6-7 correspond to diarrhea
Study: NCT04702386

Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF

Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF

Intervention type: BEHAVIORAL
Intervention: Individual interviews
Description: Interview led by the psychologist about being the child of a parent with CF
Study: NCT03986190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Juntos
Description: Parent-adolescent dyads will log in to a secured website for a total of eight weeks. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period.
Study: NCT05103423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 Injection
Description: Multiple IV infusions of BDB-001 Injection diluted in sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple IV infusions of Placebo Injection diluted in sodium chloride
Study: NCT04702386

Intervention type: BEHAVIORAL
Intervention: Individual interviews
Description: Interview led by the psychologist about being the child of a parent with CF
Study: NCT05016258

Intervention type: DEVICE
Intervention: KONTACT MB
Description: Dental implant surgery